ATE401091T1 - Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe - Google Patents

Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe

Info

Publication number
ATE401091T1
ATE401091T1 AT04768807T AT04768807T ATE401091T1 AT E401091 T1 ATE401091 T1 AT E401091T1 AT 04768807 T AT04768807 T AT 04768807T AT 04768807 T AT04768807 T AT 04768807T AT E401091 T1 ATE401091 T1 AT E401091T1
Authority
AT
Austria
Prior art keywords
vaccines
cell
based vaccines
modified whole
omv
Prior art date
Application number
AT04768807T
Other languages
English (en)
Inventor
Andrew R Gorringe
Karen M Reddin
Scott D Gray-Owen
Ian C Boulton
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE401091T1 publication Critical patent/ATE401091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04768807T 2003-10-09 2004-10-08 Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe ATE401091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0323709.6A GB0323709D0 (en) 2003-10-09 2003-10-09 Modified whole cell,cell extract and omv-based vaccines

Publications (1)

Publication Number Publication Date
ATE401091T1 true ATE401091T1 (de) 2008-08-15

Family

ID=29433617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768807T ATE401091T1 (de) 2003-10-09 2004-10-08 Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe

Country Status (12)

Country Link
US (1) US20070154495A1 (de)
EP (1) EP1687011B1 (de)
JP (1) JP2007508537A (de)
AT (1) ATE401091T1 (de)
AU (1) AU2004279990B2 (de)
CA (1) CA2541834C (de)
DE (1) DE602004015141D1 (de)
DK (1) DK1687011T3 (de)
ES (1) ES2310753T3 (de)
GB (1) GB0323709D0 (de)
PT (1) PT1687011E (de)
WO (1) WO2005035733A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027971A2 (ko) * 2009-09-01 2011-03-10 주식회사이언메딕스 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
EP2486940B1 (de) * 2009-10-08 2017-10-04 Aeon Medix Inc. Zusammensetzungen mit aus raumluft gewonnenen extrazellulären membran-vesikeln und verwendung davon
JP2011169834A (ja) * 2010-02-19 2011-09-01 Kansai Bunri Sogo Gakuen 病原性グラム陰性細菌由来脂質小胞の検出方法および検出システム
KR20160101521A (ko) * 2015-02-17 2016-08-25 이화여자대학교 산학협력단 세균 유래 세포밖 소포체를 이용한 호흡기 염증성 질환의 진단방법
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition

Also Published As

Publication number Publication date
DK1687011T3 (da) 2008-11-10
AU2004279990B2 (en) 2010-04-01
JP2007508537A (ja) 2007-04-05
EP1687011B1 (de) 2008-07-16
CA2541834A1 (en) 2005-04-21
DE602004015141D1 (de) 2008-08-28
ES2310753T3 (es) 2009-01-16
PT1687011E (pt) 2008-10-28
EP1687011A2 (de) 2006-08-09
US20070154495A1 (en) 2007-07-05
WO2005035733A3 (en) 2005-12-29
GB0323709D0 (en) 2003-11-12
CA2541834C (en) 2012-09-04
WO2005035733A2 (en) 2005-04-21
AU2004279990A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
NO20023829D0 (no) Proteosom influensavaksine
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
CY1113650T1 (el) Συντηρημενα αντιγονα neisseria
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
NZ595707A (en) Cancer antigen helper peptide
LT2287195T (lt) Antikūnai, atpažįstantys pan-kir2dl nk receptorius, ir jų panaudojimas diagnostikoje bei terapijoje
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201590597A1 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
EA200602137A1 (ru) Гидрогелевые препараты интерферона
ATE460176T1 (de) Mikrosomvakzin
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
ATE401091T1 (de) Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
ATE465753T1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
EA200970731A1 (ru) Рекомбинантные антигены цитомегаловируса человека (hcmv)
ATE513561T1 (de) Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
UA97092C2 (ru) T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение
ATE450272T1 (de) Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1687011

Country of ref document: EP